ArticleContrast media & molecular imaging2022
lncRNA SNHG12 Inhibition Based on Microsystem Cell Imaging Technology Protects the Endothelium from LPS-Induced Inflammation by Inhibiting the Expression of miR-140-3p Target Gene fndc5.
Article in Contrast media & molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Yinqiao powder effectively alleviates acute lung injury via regulating cGAS-STING signaling pathway.Frontiers of medicine · 2025Article
- LINC00365 promotes miR-221-5p to inhibit pyroptosis via Dicer in colorectal cancer.Acta biochimica et biophysica Sinica · 2024Article
- Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma.International journal of molecular sciences · 2024Article
- Gingival Tissue MiRNA Expression Profiling and an Analysis of Periodontitis-Specific Circulating MiRNAs.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) is a serious disease with a high incidence rate, characterized by uncontrolled inflammation and apoptosis. At present, long-chain noncoding RNA (lncRNA) is a noncoding RNA with a length of more than 200 nucleotides. It plays an important role in ALI, cell cycle regulation, cell differentiation regulation, and many other life activities. Therefore, the current focus is to identify and evaluate the possible functions and potential molecular mechanisms of lncRNA small nuclear host gene 12 (SNHG12). Lipopolysaccharide (LPS)-induced mice model and in vitro cell model were established. Gene knockout is to use the principle of DNA homologous recombination to replace the target gene fragment with the designed homologous fragment, so as to achieve the purpose of gene knockout. The relationship between lncRNA SNHG12 expression and ALI was studied through knockdown and overexpression experiments. The qRT-PCR, ROS, immunohistochemistry, histopathology, TUNEL, and cell permeability tests were performed to further verify the possible targets and mechanisms of action. The expression of lncRNA SNHG12 in lung tissue was lower than that in normal tissue. The results showed that lncRNA SNHG12 could reduce lung cell injury and inflammatory cytokines induced by ALI. Bioinformatics analysis showed that lncRNA SNHG12 interacted with miR-140-3p. Subsequent experiments confirmed the link between lncRNA SNHG12, miR-140-3p, and fndc5. Furthermore, this study indicates that lncRNA SNHG12 has a key function in ALI. The results of this study demonstrated the role of lncRNA SNHG12 in the pathological process of ALI and provided a reference for developing novel anti-ALI treatments so that patients can get timely treatment, avoid causing multiple organ failure, and will not endanger their life safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.